Dicerna Pharmaceuticals, Inc. DRNA

Dicerna Pharmaceuticals, Inc. Revenue 2011-2026 | DRNA

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Dicerna Pharmaceuticals, Inc.

2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
164 M	23.9 M	6.18 M	2.28 M	295 K	184 K	-	-	7.02 M	7.91 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
164 M	184 K	26.5 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
argenx SE ARGX	36.4 M	$ 834.06	0.94 %	$ 25 B	Niderland
Ascendis Pharma A/S ASND	720 M	$ 234.24	-0.3 %	$ 5 B	Danmark
Harmony Biosciences Holdings HRMY	868 M	$ 27.99	4.17 %	$ 1.59 B	USA
Acasti Pharma ACST	100 M	-	4.01 %	$ 150 M	Canada
Aptorum Group Limited APM	912 K	$ 0.81	1.31 %	$ 4.42 M	China
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
AgeX Therapeutics AGE	142 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	18.1 M	-	1.93 %	$ 17.4 M	USA
I-Mab IMAB	88 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Alterity Therapeutics Limited ATHE	109 K	$ 3.33	0.79 %	$ 8.01 B	Australia
Albireo Pharma ALBO	40.6 M	-	-0.23 %	$ 916 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
Ampio Pharmaceuticals AMPE	1.16 M	-	-11.43 %	$ 502 K	USA
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
Acer Therapeutics ACER	1.26 M	-	2.71 %	$ 14 M	USA
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
Atea Pharmaceuticals AVIR	351 M	$ 4.66	1.42 %	$ 393 M	USA
Axsome Therapeutics AXSM	638 M	$ 167.61	-4.09 %	$ 8.34 B	USA
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
Alpine Immune Sciences ALPN	30.1 M	-	-	$ 2.17 B	USA
BioDelivery Sciences International BDSI	167 M	-	-4.8 %	$ 255 M	USA
Aeterna Zentaris AEZS	9.59 M	-	5.93 %	$ 314 M	Canada
BeiGene, Ltd. BGNE	3.81 B	-	0.49 %	$ 251 B	Cayman-islands
Biogen BIIB	9.89 B	$ 194.87	-0.75 %	$ 28.5 B	USA
Bellicum Pharmaceuticals BLCM	1.5 M	-	-9.72 %	$ 5.89 M	USA
BioMarin Pharmaceutical BMRN	2.85 B	$ 63.02	0.15 %	$ 12 B	USA
Baudax Bio BXRX	1.27 M	-	0.59 %	$ 63 K	USA
Aptinyx APTX	1 M	-	-39.0 %	$ 4.57 M	USA
Aridis Pharmaceuticals ARDS	3.09 M	-	17.91 %	$ 11.1 M	USA
BioNTech SE BNTX	482 M	$ 110.88	0.86 %	$ 27.2 B	Germany
Amneal Pharmaceuticals AMRX	2.79 B	$ 14.72	2.08 %	$ 4.55 B	USA
Calithera Biosciences CALA	9.75 M	-	-10.95 %	$ 876 K	USA
Arena Pharmaceuticals ARNA	54 K	-	-6.81 %	$ 3.04 B	USA